- Post menopausal women with
osteoporosis have an increased risk for fractures.
- Injecting the drug Abaloparatide
lowers risk for fracture.
- Abaloparatide has also been found
to improve bone mineral density.
is a condition in which the bones become weak and the individual is at high risk for hip fractures. There are no symptoms associated with osteoporosis till the individual breaks a bone, which is why it is called a silent disease.
The risk factors
associated with osteoporosis include:
- Small and thin frame
- Older women
- Low bone density or osteopenia
- Post menopausal women
- One in two women suffer from
- One in four men suffer from
- The lifetime risk of fractures for
a women of age 60 is 44%
- 54 million Americans suffer from
- The medical costs incurred due to
osteoporosis is 34 million dollars in the U.S
Bone Fractures among
Osteoporotic Men and Women
can be very painful as it requires hospitalization and additional care that
would generally affect the quality of life of senior citizens. Fractures
that are caused due to osteoporosis could occur without any excessive physical
injury, even minor falls could lead to a fracture.
‘Injection of drug Abaloparatide found to decrease fracture risk for women with osteoporosis.’
Older people are often left worrying
about fractures and activities that involve a fair amount of physical exertion.
This stresses the need to find a preventive mechanism that safeguard older adults
from the risk of fractures.
Abaloparatide on Lowering Fracture Risk among Osteoporotic Women
Dr Paul and
colleagues from the Colorado Center for Bone Research tested 2 different drugs
and a placebo on randomly selected women with osteoporosis. There were 3 groups
of study participants
- 824 women with osteoporosis
received injections of Abaloparatide
- 818 women with osteoporosis
received injections of Teriparatide
- 821 women with osteoporosis
received injections of Placebo
The study was
conducted across 10 countries and 28 sites with injections administered for 18
months. 2463 participated with an average age of 69 years were included in the
study and 1901 women completed the study.
fractures were seen in
- 0.58% in the Abaloparatide group.
- 0.84% in the Teriparatide group.
- 4.22% in the Placebo group.
than vertebra like hip or other bones that was estimated were
- 2.7% in the Abaloparatide group.
- 3.3% in the Teriparatide group.
- 4.7% in the Placebo group.
of using Abaloparatide were -
- Bone mineral density was found to
increase when compared with placebo
- The incidence of hypercalcemia was
lower in abaloparatide group than in teriparatide group.
The use of
abaloparatide shows a lot of promise in lowering the risk of fractures among
women with osteoporosis. However, the authors include a note of caution, "Further research is needed to understand the clinical
importance of risk difference, the risks and benefits of abaloparatide
treatment, and the efficacy of abaloparatide vs other osteoporosis
- Osteoporosis - (https://medlineplus.gov/osteoporosis.html)
- What is Osteoporosis and What
Causes It? - (https://www.nof.org/patients/what-is-osteoporosis/)
- Injected drug
reduces risk of fracture among women with osteoporosis - (http://www.eurekalert.org/emb_releases/2016-08/tjnj-